Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature;Potentialités cliniques et perspectives d'utilisation de l'aripiprazole hors de ses champs classiques d'indication. Analyse critique des données de la littérature récente

Encephale

Volumn 34, Issue 2, 2008, Pages 187-193

  Crocq, M A ^a,b   Camus, V ^c   Millet, B ^d   Glickman, J ^e   Azorin, J M ^f   Krebs, M O ^g   Limosin, F ^h   Costentin, J ⁱ   Dalery J ^j  

^a Centre Hospitalier de Rouffach   (France)

^b UNIVERSITÉ DE HAUTE ALSACE   (France)

^c CHU BRETONNEAU   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e centre médico psychologique Sémion Gluzman   (France)

^f HÔPITAL SAINTE MARGUERITE   (France)

^g CENTRE HOSPITALIER SAINTE ANNE   (France)

^h SERVICE DE DERMATOLOGIE   (France)

ⁱ HÔPITAL CHARLES NICOLLE   (France)

^j cente hospitalier Le Vinatier   (France)

more..

Author keywords

Addiction; Adolescents; Anxiety; Aripiprazole; Borderline personality; Children; Depression; Elderly; Obsessive compulsive disorder; Tourette

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SULPIRIDE;

ADDICTION; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; BORDERLINE STATE; CHILD PSYCHIATRY; CLINICAL TRIAL; DELIRIUM; DELUSION; DEPRESSION; DRUG INDICATION; DYSPHORIA; ELDERLY CARE; EXTRAPYRAMIDAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PARKINSON DISEASE; SEDATION; SIDE EFFECT;

AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; TOURETTE SYNDROME;

EID: 44149095720     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2007.12.004     Document Type: Article

References (53)

1. Adson D.E., Kushner M.G., and Fahnhorst T.A. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 86 (2005) 99-104
2. Alao A.O., Soderberg M., Pohl E.L., et al. Aripiprazole in the treatment of delirium. Int J Psychiatry Med 35 4 (2005) 429-433
3. Alexopoulos G.S., Streim J., Carpenter D., et al. Using antipsychotic agents in older patients. J Clin Psychiatry 65 Suppl 2 (2004) 5-99
4. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry 154 (1989) 672-676
5. Barzman D.H., DelBello M.P., Kowatch R.A., et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol 14 (2004) 593-600
6. Behere R.V., Venkatasubramanian G., Naveen M.N., et al. Aripiprazole-induced hyponatremia: a case report. J Clin Psychiatry 68 4 (2007) 640-641
7. Beresford T.P., Clapp L., Martin B., et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 25 (2005) 363-366
8. Berman RM, Marcus RN, Swanink R, et al. Efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder. A multicenter, randomized, double-blind, placebo-controlled study. Poster NR 310; American Psychiatric Association 160th annual meeting, San Diego, CA, May 19-24, 2007.
9. Biederman J., McDonnell M.A., Wozniak J., et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectrum 10 (2005) 141-148
10. Blumer J.L., Findling R.L., Kauffman R., et al. Pharmacokinetics, tolerability and safety of aripiprazole in children and adolescents with conduct disorder. Clin Pharmacol Ther 71 (2002) P5 [abstract]
11. Boettger S., and Breitbart W. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care 3 3 (2005) 227-237
12. Brown E.S., Jeffress J., Liggin J.D., et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 66 (2005) 756-760
13. Connor K.M., Payne V.M., Gadde K.M., et al. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66 (2005) 49-51
14. Davies L., Stern J.S., Agrawal N., et al. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol Clin Exp 21 (2006) 447-453
15. De Deyn P., Jeste D.V., Swanink R., et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 25 5 (2005) 463-467
16. Feltenstein M.W., Altar C.A., and See R.E. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry 61 5 (2007 Mar 1) 582-590
17. Fernandez H.H., Trieschmann M.E., and Friedman J.H. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 27 1 (2004) 4-5
18. Findling R.L., Blumer J.L., Kauffman R., et al. Aripiprazole in pediatric conduct disorder: a pilot study. Eur Neuropsychopharmacol 13 Suppl 4 (2003) S335
19. Finkel S., Costa e Silva J.A., Cohen G., et al. Behavioural and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr (1996) 497-500
20. Friedman A., and Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 84 2 (1991) 111-113
21. Friedman J.H. Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning. Neurology 67 4 (2006) 564-566
22. Gao K., Muzina D., Gajwani P., et al. Efficacy of typical and atypical antipsychotics for primary or comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 67 (2006) 1327-1340
23. Grant M.J., and Baldessarini R.J. Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 39 11 (2005) 1953
24. Hellerstein D.J. Aripiprazole as an adjunctive treatment for refractory major depression. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 1347-1348
25. Hollis J., Touyz S., Grayson D., et al. Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001. Aust N Z J Psychiatry 40 11-12 (2006) 981-986
26. Ingman K., Kupila J., Hyytia P., et al. Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol 41 4 (2006 Jul-Aug) 391-398 Epub 2006 May 9
27. 1A receptor. Eur J Pharmacol 441 (2002) 137-140
28. Kastrup A., Schlotter W., Plewnia C., et al. Treatment of tics in Tourette syndrome with aripiprazole. J Clin psychopharmacol 25 (2005) 94-96
29. Kemp D.E., Gilmer W.S., Fleck J., et al. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 574-577
30. Lopez-Meza E., Ruiz-Chow A., and Ramirez-Bermudez J. Aripiprazole in psychosis associated with Parkinson's disease. J Neuropsychiatry Clin Neurosci 17 3 (2005) 421-422
31. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340 10 (1999) 757-763
32. Madhusoodanan S., Brenner R., Gupta S., et al. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr 9 11 (2004) 862-867
33. Möller H.J. Antipsychotic and antidepressive effects of second generation antipsychotics. Two different pharmacological mechanisms. Eur Arch Psychiatry Clin Neurosci 255 (2005) 190-201
34. Nickel M.K., Loew T.H., and Pedrosa Gil F. Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology 191 (2007) 1023-1026
35. Nickel M.K., Muehlbacher M., Nickel C., et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 163 (2006) 833-838
36. Pae C.U., Patkar A.A., Jun T.Y., et al. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety (2006) 1-5
37. Pollak P., Tison F., Rascol O., et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow-up. J Neurol Neurosurg Psychiatry 75 5 (2004) 689-695
38. Robb AS, Findling RL, Nyilas M, et al. Efficacy of aripiprazole in the treatment of schizophrenia. Poster NR 742; American Psychiatric Association 160th Annual Meeting, San Diego, CA, May 19-24, 2007.
39. Rugino T.A., and Janvier Y.M. Aripiprazole in children and adolescents: clinical experience. J Child Neurol 7 (2005) 603-610
40. Sajatovic M., Madhusoodanan S., and Coconcea N. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs Aging 22 1 (2005) 39-54
41. Salmoiraghi A., and Odiyoor M. A case of aripiprazole and extrapyramidal side effects. J Psychopharmacol 20 4 (2006) 592-593
42. Schneider L.S., Dagerman K., and Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14 3 (2006) 191-210
43. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294 15 (2005) 1934-1943
44. Schwabe K., and Koch M. Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats. Psychopharmacology 191 (2007) 759-765
45. Sharma A., and Sorrell J.H. Aripiprazole-induced parkinsonism. Int Clin Psychopharmacol 21 2 (2006) 127-129
46. Singh S., and Wooltorton E. Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ 173 3 (2005) 252
47. Stigler K.A., Posey D.J., and McDougle C.J. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14 (2004) 455-463
48. Storch E.A., Lehmkuhl H., Geffken G.R., et al. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety (2007) 1-3
49. Straker D.A., Shapiro P.A., and Muskin P.R. Aripiprazole in the treatment of delirium. Psychosomatics 47 5 (2006) 385-391
50. Warsi M., Sattar S.P., Bhatia S.C., et al. Aripiprazole reducs alcohol use. Can J Psychiatry 50 (2005) 244
51. Wickremaratchi M., Morris H.R., and Ali I.M. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 21 9 (2006) 1538-1539
52. Witschy J.K., and Winter A.S. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry 50 3 (2005) 188
53. Worthington III J.J., Kinrys G., and Wygant L.E. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 20 (2005) 9-11